Danielle Nicole Larson, MD, discusses the mental health burden on patients with tardive dyskinesia, and considerations for clinicians who manage this condition.

Dec 22 () - Neurocrine Biosciences said on Monday its drug failed to meet the ​main goal in a late-stage clinical trial ‌in patients with a type of disorder that disrupts the ‌brain's ability to ...

Patients on antipsychotics need to be regularly monitored for signs of tardive dyskinesia, a medication-induced movement disorder diagnosed when the involuntary movements persist for at least a month ...

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

In an exclusive interview with 'Parade,' singer Carnie Wilson spoke about advocating for those with TD, her career as a musician, and her father, Brian Wilson.

Evoke Stockholders Received $11.00 Per Share in Cash SOLANA BEACH, Calif., and VERO BEACH, Fla., Dec. 17, 2025 /PRNewswire/ -- Evoke Pharma, Inc. (formerly NASDAQ: EVOK) ("Evoke") and QOL Medical, LLC ...

Evoke Stockholders Received $11.00 Per Share in Cash SOLANA BEACH, Calif., and VERO BEACH, Fla., Dec. 17, 2025 /PRNewswire/ -- Evoke Pharma, Inc. (formerlyNASDAQ: ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety ...

Essential tremor (ET) is a common movement disorder affecting about 2% of the American population, and more than 20% of those over 90 years old. Despite its prevalence and decades of study, ...

The human brain is a fascinating and complex organ that supports numerous sophisticated behaviors and abilities that are ...